Abstract
Most cancer therapies are seldom effective by using single anticancer drug therapeutics based on multiple tumor genetic alterations and molecular abnormalities. Drug combinations are commonly practiced in clinics. Yet, anticancer drug combination utilities need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapies by mathematical enquiry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have